American Society of Hirudotherapy

Comparative Study of Lefaxin Family in Two Asian Leeches: Hirudinaria manillensis and Whitmania pigra

Ye T, Zhao F, Xiao M, Yin J, Ai R, Tang L, Liu Z, Huang Z, Lin G (2025) · Biology

Preclinical / molecular study: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Model / material
genomic and transcriptomic sequencing of wild populations of Hirudinaria manillensis and Whitmania pigra with recombinant expression of lefaxin proteins and in-vitro Factor Xa anticoagulant activity assays (Chinese consortium led by Jinggangshan University)
Method
Comparative characterization of three lefaxin genes per species, plus recombinant lefaxin protein expression and in-vitro anticoagulant assays
Main result
Hirudinaria manillensis lefaxins bound Factor Xa more effectively; Whitmania pigra lefaxins showed more robust in-vitro anticoagulant activity despite W. pigra being non-hematophagous; H. manillensis exhibited higher genetic diversity and stability; finding challenges traditional view that non-hematophagous leech species lack potent anticoagulants

Key Findings

  • Three lefaxin genes per species (LefH1-3 in H. manillensis, LefW1-3 in W. pigra)
  • W. pigra lefaxins more potent in-vitro despite non-hematophagous ecology
  • H. manillensis lefaxins better Factor Xa binders
  • Provides recombinant protein expression workflow for both species
  • Challenges traditional view that only blood-feeders have potent anticoagulants

Limitations

  • In-vitro biochemistry only — no in-vivo or clinical efficacy
  • Recombinant proteins may differ from native molecules in folding or post-translational modification
  • Limited population sampling
  • No comparison to gold-standard recombinant hirudin or bivalirudin
  • No mammalian pharmacokinetic or safety data

Clinical Implications

Ye 2025 deepens the comparative pharmacology of underrepresented Asian medicinal-leech species and demonstrates that Whitmania pigra lefaxins are clinically interesting anticoagulant candidates despite the species' non-hematophagous ecology. For ASH, the finding reinforces that 'medicinal leech' pharmacology is species-heterogeneous and that K040187 US clinical practice should not be conflated with global research on Asian Hirudinaria, Whitmania, or Haemadipsa species. Translational drug-discovery relevance only.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.